Merck & Co has quietly added another drug to its immuno-oncology pipeline via an agreement with China's Sichuan Kelun Pharmaceutical, and is keeping the details close to its chest. The US pharma ...

Merck (NYSE:MRK) is doubling down on China's biotech boomthis time with a $2 billion licensing deal for a potential blockbuster heart drug from Jiangsu Hengrui Pharmaceuticals. The deal gives ...

Per the deal terms, Merck (NYSE:MRK) will receive exclusive rights to develop, manufacture, and commercialize HRS-5346 globally except in Greater China. In exchange, the Rahway, New Jersey-based ...

Germany’s Merck KGaA has signed a collaboration with Tencent to develop digital healthcare services in China. Darmstadt-based Merck’s strategic tie-up with the China-based multinational tech ...

Most recently, Danish drugmaker Novo Nordisk bought global rights to China-based United Laboratories International's weight-loss drug candidate in a deal worth up to $2 billion. Merck last year ...